|
May 14
|
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
|
|
May 11
|
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
|
|
May 10
|
Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
|
|
May 10
|
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations
|
|
May 9
|
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 9
|
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 2
|
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
|
|
Apr 28
|
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
|
|
Mar 28
|
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
|
|
Mar 28
|
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
|
|
Mar 28
|
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
|
|
Mar 26
|
Akebia Awaits FDA Word On Second Crack At Vadadustat
|
|
Mar 17
|
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
|
|
Mar 16
|
Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
|
|
Mar 14
|
Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter
|
|
Mar 14
|
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
|
|
Mar 14
|
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
|
Mar 11
|
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 9
|
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
|